Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -183.44% is 233% below its 5-year average of -55.17%, near the low end of its 5-year range (-183.44%–-15.27%).
As of the fiscal period ended Tuesday, June 30, 2026. 23.10% below its 12-month average of -149.01%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -183.44%.
RETURN ON EQUITY (ROE)
-183.44%
RETURN ON EQUITY (ROE) AVG TTM
-149.01%
RETURN ON EQUITY (ROE) AVG 3Y
-78.94%
RETURN ON EQUITY (ROE) AVG 5Y
-55.17%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-23.10%
CURRENT VS 3Y AVG
-132.39%
CURRENT VS 5Y AVG
-232.52%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-37.66%
median of 436 covered companies
CURRENT VS SECTOR MEDIAN
-387.10%
vs the sector median at left
Acumen Pharmaceuticals, Inc.
Market Cap
$153.84M
Return on Equity (ROE)
-183.44%
TTM Avg
-149.01%
3Y Avg
-78.94%
5Y Avg
-55.17%
Market Cap
$152.45M
Return on Equity (ROE)
-21.38%
TTM Avg
-42.33%
3Y Avg
-37.95%
5Y Avg
-45.57%
Market Cap
$152.16M
Return on Equity (ROE)
-155.34%
TTM Avg
-168.75%
3Y Avg
-117.97%
5Y Avg
-104.46%
Market Cap
$149.51M
Return on Equity (ROE)
-93.22%
TTM Avg
-92.28%
3Y Avg
-73.94%
5Y Avg
-53.80%
Market Cap
$160.82M
Return on Equity (ROE)
-14.07%
TTM Avg
-16.23%
3Y Avg
-27.66%
5Y Avg
-19.01%
Market Cap
$146.66M
Return on Equity (ROE)
-30.03%
TTM Avg
-86.56%
3Y Avg
-69.53%
5Y Avg
-37.30%
Market Cap
$162.82M
Return on Equity (ROE)
-59.40%
TTM Avg
-255.06%
3Y Avg
-160.44%
5Y Avg
-112.56%
Market Cap
$143.81M
Return on Equity (ROE)
-131.85%
TTM Avg
-36.69%
3Y Avg
-135.43%
5Y Avg
-129.92%
Market Cap
$142.49M
Return on Equity (ROE)
68.12%
TTM Avg
-94.32%
3Y Avg
-166.28%
5Y Avg
-128.51%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | $153.84M | -183.44% | -149.01% | -78.94% | -55.17% |
| Anavex Life Sciences Corp. (AVXL)vs › | $152.45M | -21.38% | -42.33% | -37.95% | -45.57% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $152.16M | -155.34% | -168.75% | -117.97% | -104.46% |
| Codexis, Inc. (CDXS)vs › | $149.51M | -93.22% | -92.28% | -73.94% | -53.80% |
| Inogen, Inc. (INGN)vs › | $160.82M | -14.07% | -16.23% | -27.66% | -19.01% |
| Immuneering Corporation (IMRX)vs › | $146.66M | -30.03% | -86.56% | -69.53% | -37.30% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $162.82M | -59.40% | -255.06% | -160.44% | -112.56% |
| Korsana Biosciences, Inc. (KRSA)vs › | $143.81M | -131.85% | -36.69% | -135.43% | -129.92% |
| Fortress Biotech, Inc. (FBIOP)vs › | $142.49M | 68.12% | -94.32% | -166.28% | -128.51% |
| Alpha Cognition Inc (ACOG)vs › | $142.11M | -44.26% | -34.18% | 285.39% | -5868.11% |
ROE
-183.4%
ROA
-90.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -183.44% |
| 2026-03-31 | -129.49% |
| 2025-12-31 | -172.28% |
| 2025-09-30 | -143.12% |
| 2025-06-30 | -116.73% |
| 2025-03-31 | -74.75% |
| 2024-12-31 | -56.28% |
| 2024-09-30 | -37.60% |
| 2024-06-30 | -26.59% |
| 2024-03-31 | -21.35% |
| 2023-12-31 | -19.62% |
| 2023-09-30 | -17.39% |
| 2023-06-30 | -27.53% |
| 2023-03-31 | -25.15% |
| 2022-12-31 | -22.70% |
| 2022-09-30 | -19.50% |
| 2022-06-30 | -15.27% |
| 2022-03-31 | -38.29% |
| 2021-12-31 | -44.68% |
| 2021-09-30 | -39.86% |
